Russo Rene
Insider CIK 1722066 · ASNS President and CEO, Director · ADGI Director · XLO PRESIDENT AND CEO, Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics, Inc. | M Exercise deriv | 2026-01-01 | 2026-01-05 | 44,250 | — | $0 | 88,500 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise | 2026-01-01 | 2026-01-05 | 44,250 | — | $0 | 325,422 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-12-31 | 2026-01-05 | 1,500,258 | — | $0 | 1,500,258 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 150,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 700,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 700,000 | — | $0 | 700,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 350,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 100,000 | — | $0 | 100,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 100,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 50,041 | — | $0 | 50,041 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 50,041 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 135,134 | — | $0 | 135,134 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 135,134 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 473,334 | — | $0 | 473,334 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 2,075,000 | — | $0 | 2,075,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 239,703 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 239,703 | — | $0 | 239,703 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 473,334 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-11-21 | 2025-11-25 | 350,000 | — | $0 | 350,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | D To issuer deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 0 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2025-06-16 | 2025-06-18 | 36,289 | $0.68 | $24.7K | 281,172 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-04-15 | 2025-04-16 | 190,000 | — | $0 | 190,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2025-01-01 | 2025-01-03 | 638,000 | — | $0 | 638,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise deriv | 2025-01-01 | 2025-01-03 | 44,250 | — | $0 | 132,750 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | M Exercise | 2025-01-01 | 2025-01-03 | 44,250 | — | $0 | 244,883 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2024-05-01 | 2024-05-03 | 474,000 | — | $0 | 474,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2024-01-01 | 2024-01-03 | 177,000 | — | $0 | 177,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2023-08-16 | 2023-08-18 | 700,000 | — | $0 | 700,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2023-01-01 | 2023-01-04 | 350,000 | — | $0 | 350,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2022-02-22 | 2022-02-24 | 150,000 | — | $0 | 150,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2021-12-22 | 2022-01-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2021-12-22 | 2021-12-23 | 100,000 | — | $0 | 100,000 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | A Award deriv | 2021-10-21 | 2021-10-25 | 50,041 | — | $0 | 50,041 | SEC↗ |
| ADGI Adagio Therapeutics, Inc. | A Award deriv | 2021-08-05 | 2021-08-09 | 35,593 | — | $0 | 35,593 | SEC↗ |
| XFOR X4 Pharmaceuticals, Inc | A Award deriv | 2021-06-02 | 2021-06-02 | 6,000 | $9.50 | $57.0K | 6,000 | SEC↗ |
| XFOR X4 Pharmaceuticals, Inc | A Award deriv | 2020-06-10 | 2020-06-11 | 3,427 | — | $0 | 3,427 | SEC↗ |
| XFOR X4 Pharmaceuticals, Inc | A Award deriv | 2019-06-17 | 2019-06-19 | 3,427 | — | $0 | 3,427 | SEC↗ |
| ASNS Arsanis, Inc. | A Award deriv | 2018-03-07 | 2018-03-09 | 160,000 | — | $0 | 160,000 | SEC↗ |